Table 3.

SABA prescriptions in the 12 months before the study visit in the SABINA III Turkey Cohort

	All (N = 579)	Patients classified by asthma severity (n = 568)*
		Investigator-classified mild asthma (n = 98)	Investigator-classified moderate-to-severe asthma (n = 470)
Patients prescribed SABA monotherapy, n (%)
Yes	33 (5.7)	18 (18.4)	14 (3.0)
No	546 (94.3)	80 (81.6)	456 (97.0)
Number of SABA canisters or inhalers per patient prescribed 12 months before the study visit
Number of patients	31	17	13
Mean (SD)	4.2 (3.9)	2.7 (3.5)	5.9 (3.8)
Median (min, max)	2.0 (1.0, 12.0)	2.0 (1.0, 12.0)	6.0 (2.0, 12.0)
Number of SABA canisters or inhalers (as categories) per patient prescribed 12 months before the study visit, n (%)
0–2	20 (64.5)	15 (88.2)	5 (38.5)
3–5	0 (0.0)	0 (0.0)	0 (0.0)
6–9	6 (19.4)	0 (0.0)	5 (38.5)
10–12	5 (16.1)	2 (11.8)	3 (23.1)
≥ 13	0 (0.0)	0 (0.0)	0 (0.0)
Number of missing values	2	1	1
Total	31	17	13
Patients prescribed SABA in addition to maintenance therapy, n (%)
Yes	356 (61.5)	40 (40.8)	308 (65.5)
No	223 (38.5)	58 (59.2)	162 (34.5)
Number of SABA canisters or inhalers per patient prescribed 12 months before the study visit
Number of patients	222	30	189
Mean (SD)	3.5 (3.2)	2.2 (2.3)	3.7 (3.3)
Median (min, max)	2.0 (1.0, 16.0)	2.0 (1.0, 12.0)	2.0 (1.0, 16.0)
Number of SABA canisters or inhalers per patient prescribed 12 months before the study visit in categories, n (%)
0–2	127 (57.2)	25 (83.3)	101 (53.4)
3–5	52 (23.4)	3 (10.0)	48 (25.4)
6–9	27 (12.2)	1 (3.3)	25 (13.2)
10–12	12 (5.4)	1 (3.3)	11 (5.8)
≥ 13	4 (1.8)	0 (0.0)	4 (2.1)
Number of missing values	134	10	119
Total	222	30	189

Max, maximum; min, minimum; SABA, short-acting β₂-agonist; SABINA, SABA use IN Asthma; SD, standard deviation

*Asthma severity data are reported for 568 patients and not for the six patients with missing data or the five patients erroneously categorised under primary care